ADTX - The Buzz Show: Aditxt (NASDAQ: ADTX) Toxicity Study Psoriasis Drug Candidate ADI(TM)-100

FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Aditxt , Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI -100 ”

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system, today announces that its therapeutic program Adimune , has successfully completed a toxicology study that indicates the safety profile of ADI -100, the Company’s immunotherapeutic technology drug that addresses rejection of transplanted organs, skin allografting, autoimmune diseases and allergies.

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

For more information, please visit: Aditxt, Inc.

About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.

The post “The Buzz” Show: Aditxt (NASDAQ: ADTX) Toxicity Study Psoriasis Drug Candidate ADI™-100 first appeared on Financial Buzz .

For further details see: